prometheus biosciences:Prometheus Biosciences
Prometheus Biosciences
2023年6月26日—PrometheusBiosciences,Inc.(RXDX.US)成立於2016年,總部位於美國加州聖地牙哥,前身為PrecisionIBD,Inc.,2019年10月更為現名,為一家生物製藥 ...。其他文章還包含有:「MerckCompletesAcquisitionofPrometheusBiosciences」、「MerckStrengthensImmunologyPipelinewithAcquisitionof...」、「MercktobuyPrometheusBiosciencesforabout$11billion」、「OurStory」、「PrometheusBiosciences」、「PrometheusBi...
查看更多 離開網站Merck Completes Acquisition of Prometheus Biosciences
https://www.merck.com
Prometheus is now a wholly-owned subsidiary of Merck and the common stock of Prometheus will no longer be listed or traded on the Nasdaq Global ...
Merck Strengthens Immunology Pipeline with Acquisition of ...
https://www.merck.com
Prometheus Biosciences, Inc. is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, ...
Merck to buy Prometheus Biosciences for about $11 billion
https://www.reuters.com
Merck & Co said on Sunday it will buy Prometheus Biosciences Inc for about $10.8 billion, picking up a promising experimental treatment for ...
Our Story
https://www.prometheusbioscien
At Prometheus Biosciences, we aim to transform the paradigm of patient care with a proprietary precision-based approach to IBD and immune-mediated diseases.
Prometheus Biosciences
https://www.crunchbase.com
Prometheus Biosciences develops and commercializes pharmaceutical and diagnostic products to help physicians individualize patient care.
Prometheus Biosciences
https://www.prometheusbioscien
Prometheus Biosciences is a biotechnology company specializing in developing precision therapies for immune-mediated diseases using a one-of-a-kind ...
Prometheus Pipeline
https://www.prometheusbioscien
Prometheus Biosciences has a robust pipeline of therapeutic development programs to address several clinical IBD patient subpopulations.
瞄準免疫治療商機默沙東收購Prometheus Biosciences
https://tw.stock.yahoo.com
美國製藥巨頭默沙東(Merck & Co.)16日宣布,斥資108億美元收購生技公司Prometheus Biosciences,藉此將前景看好的免疫疾病治療納入麾下, ...
默克公司將以108億美元收購Prometheus Bioscience
https://cn.wsj.com
默克公司(Merck & Co. Inc. ,MRK)宣布,同意以108億美元收購Prometheus Biosciences Inc. ,以進軍利潤豐厚的免疫疾病治療市場。 默克公司周日表示, ...